Empirical Proton‑Pump Inhibitor Therapy as First‑Line Management for H. pylori‑Negative Functional Dyspepsia

First‑Line Pharmacologic Recommendation

• Oral omeprazole (or any appropriately dosed PPI) is the most appropriate initial pharmacologic agent for adult patients with H. pylori‑negative functional dyspepsia while awaiting endoscopy. Strong recommendation; high‑quality evidence. 1
• PPIs are strongly recommended as first‑line empirical therapy for H. pylori‑negative dyspepsia, demonstrating superiority over placebo, H₂‑receptor antagonists, and antacid‑alginate combinations. High‑quality evidence. 1
• The British Society of Gastroenterology (2022) issues a strong recommendation, based on high‑quality evidence, that patients without H. pylori infection should receive empirical acid‑suppression therapy. 1

Dosing and Administration

• Standard‑dose PPI (omeprazole 20 mg) should be taken once daily 30–60 minutes before a meal for 4–8 weeks; if symptoms persist, the dose may be escalated to twice daily for an additional 4–8 weeks. 1

Adjunctive Non‑Pharmacologic Measures

• Regular aerobic exercise is advised as an adjunctive measure, supported by a strong recommendation. 1

Diagnostic Pathway

• An upper endoscopy should be scheduled to exclude structural disease in all adult patients with functional dyspepsia. 1

Second‑Line Pharmacologic Options (After PPI Failure)

• Tricyclic antidepressants (e.g., amitriptyline) are recommended as second‑line therapy for patients who fail initial PPI treatment. Strong recommendation; moderate‑quality evidence. 1
• Amitriptyline should be initiated at a low dose (≈10 mg once daily) and titrated slowly to a maximum of 30–50 mg daily, with thorough counseling regarding rationale and potential side effects. Moderate‑quality evidence. 1

Treatments Not Recommended for Functional Dyspepsia

All three agents are unsupported by evidence for functional dyspepsia management.* 1

Additional Clinical Considerations

• A negative H. pylori test eliminates the need for eradication therapy, reinforcing empirical PPI as the clear first choice. Strong recommendation; high‑quality evidence. 1
• Even when dysmotility‑like symptoms (early satiety, bloating) are present, PPIs remain the first‑line treatment; prokinetics may be added only after adequate PPI trial. Strong recommendation; high‑quality evidence. 1

PPI Therapy and H. Pylori Eradication

Initial PPI Therapy and Efficacy

• The American College of Gastroenterology recommends beginning with standard-dose PPI once daily, taken 30-60 minutes before a meal, for 4-8 weeks as first-line therapy for acid peptic disease and dyspepsia, with all commercially available PPIs having similar efficacy for symptom control 2
• PPIs are superior to H2-receptor antagonists, which are superior to placebo, in treating acid peptic disease and dyspepsia 2

PPI Step-Up Protocol

• If symptoms persist after 4-8 weeks of once-daily PPI therapy, increase to twice-daily dosing (morning and evening) before meals, and continue twice-daily dosing for an additional 4-8 weeks 2, 3
• For dysmotility-like symptoms (bloating, fullness, early satiety), add prokinetic agent 4, 3

H. Pylori Eradication Protocols

• Test for H. pylori using urea breath test or stool antigen test in patients <60 years with dyspepsia; eradicate if positive, with first-line eradication regimens including bismuth quadruple therapy or concomitant therapy 5
• H. pylori eradication eliminates peptic ulcer mortality risk but may not resolve all dyspeptic symptoms 6, 4

Symptom-Based Therapy

• For ulcer-like dyspepsia (epigastric pain predominant), use full-dose PPI (omeprazole 20 mg once daily) as first choice, with response confirming acid-related nature of symptoms 6, 4
• For dysmotility-like dyspepsia (fullness, bloating, early satiety predominant), use prokinetic agent as first choice, avoiding cisapride due to cardiac toxicity 6, 4

Important Considerations

• PPIs should be taken 30-60 minutes before meals for optimal effect, and H2-receptor antagonists may develop tolerance within 6 weeks, limiting long-term effectiveness 3
• If symptoms persist despite optimized PPI therapy (twice daily for 8 weeks), endoscopy is indicated 2, 3

Management of Persistent Dyspepsia after Initial PPI Therapy

Escalation of Proton‑Pump Inhibitor Dosing

• For patients whose dyspeptic symptoms persist after an initial 4–8 week course of once‑daily proton‑pump inhibitor (PPI) therapy, the guideline recommends escalating to twice‑daily dosing (morning and evening before meals) for an additional 4–8 weeks. 7

Further Diagnostic Evaluation

• If symptoms remain despite optimized twice‑daily PPI therapy for up to 8 weeks, the recommendation is to perform upper endoscopy and consider off‑medication prolonged wireless pH monitoring to confirm or exclude gastro‑esophageal reflux disease. 7

Role of Alarm Symptoms in Decision‑Making

• In the absence of alarm features such as dysphagia, gastrointestinal bleeding, anemia, unintended weight loss, or recurrent vomiting, empirical PPI therapy is advised rather than immediate endoscopic investigation. 8